Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > INBT Speakers Highlight Nanobio Trends in Neuroscience, Stem Cell Growth, Drug Delivery, Imaging

Abstract:
Below is the first part of a two-part series summarizing the talks presented at the 3rd Annual NanoBio Symposium hosted by the Johns Hopkins Institute for NanoBioTechnology, on May 18, 2009. Five talks from the eight speakers who presented that day are described below.

INBT Speakers Highlight Nanobio Trends in Neuroscience, Stem Cell Growth, Drug Delivery, Imaging

Baltimore, Md | Posted on June 24th, 2009

Novel Approaches to Understand Neurodegenerative and Neuropsychiatric Diseases

Ted Dawson - Leonard and Madlyn Abramson Professor of Neurodegenerative Diseases, Department of Neurology; Institute for Cell Engineering, Johns Hopkins School of Medicine

Inducible pluripotent stem cells (iPS) derived from patients with Parkinson's disease, schizophrenia, autism spectrum disorders, Down syndrome and other neurodegenerative or neuropsychiatric conditions could become better tools to study disease processes than mouse models, which lack certain genetic markers found in humans. By transplanting human-derived iPS cells that exhibit neurological conditions into animals, scientists could create human disease-specific models that will serve as the drug screening platform for the future. The Institute for Cell Engineering works with scientists from INBT to use nanofibers, quantum dots and other methods to control and direct differentiation of iPS cells into neurological cells, such as astrocytes, oligodendrocytes and neurons. (by Mary Spiro)

Developing Contrast Agents for Imaging Drug Delivery

Michael McMahon - Assistant Professor, Radiology/MR Division; FM Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Johns Hopkins School of Medicine

Contrast agents are often used in conjunction with medical imaging to enhance images. Michael McMahon explained how he and his colleagues are developing magnetic resonance contrast agents based on the imaging technique Chemical Exchange Saturation Transfer (CEST) that exhibit distinct colors similar to fluorescent agents. They recently incorporated these contrast agents into liposomes, which are vehicles for drug delivery. They injected the liposomes into mice and detected the contrast agent at various times post-injection. Due to their distinct colors, CEST-based contrast agents could prove useful for imaging drug delivery and release in humans. (by Adam Book)

Using Nanotechnology to Guide Blood Vessel Formation

Sharon Gerecht - Assistant Professor, Department Chemical and Biomolecular Engineering; Institute for NanoBioTechnology; Whiting School of Engineering, Johns Hopkins University

Stem cells can become a wide variety of specialized cell types. One type of stem cell, the endothelial progenitor cell (EPC), grows into cells that form blood vessels. Sharon Gerecht described how she is developing surfaces that guide EPCs into forming blood vessels. They grew EPCs on either flat or nanotopographic surfaces. Cells on the flat surface grew randomly, while cells on the nanotopographic surface aligned with the nanoscale etchings. Gerecht is currently determining the best way to persuade the cells to form the proper three-dimensional organization of living blood vessel networks. (by Adam Book)

Directing Stem Cell Fate with Nanofiber Matrices

Hai-Quan Mao - Assistant Professor, Department of Materials Science and Engineering, Whitaker Biomedical Engineering Institute; Whiting School of Engineering, Johns Hopkins University

The use of stem cells to replace diseased tissues in the body is a promising avenue of research. However, this therapy depends on the stem cells surviving and growing into the correct type of cell after being placed in the body. Hai-Quan Mao talked about a technique for growing neural stem cells on nanofiber matrices, which can be manipulated to form the various environments found in the human body. By altering the nanotopography of the matrix and adding chemical cues, they can coax a neural stem cell to differentiate into a desired cell type. (by Adam Book)

Future Applications of Nanotechnology for the Treatment of Brain Tumors

Alessandro Olivi - Professor, Neurosurgery and Oncology; Chair, Department of Neurosurgery, Johns Hopkins Bayview Medical Center

Recent neurosurgical advances in imaging, preoperative planning, microsurgical techniques, and intra-operative and post-operative patient care are improving the treatment of brain tumors. Better imaging allows more precise targeting of the affected area and the determination of the optimal trajectory for procedures that are minimally invasive and more respectful of function. The use of nanoparticles for drug delivery, targeted nanoparticle immunotherapy, thermotherapy, photodynamic therapy, intracellular delivery, and the use of nanoparticles to increase MRI image delineation of brain tumors holds much promise with increased survival time. Targeted immunotherapy includes intercellular delivery and delivery via incapsulation and coating. Targeted drug delivery of chemotherapy agents over a three to four week period at the level of the tumor bed is now possible via the Gliadel Wafer. The use of nanotechnology will likely bring us to the next level in the treatment of malignant brain tumors. (by Gina Hagler)

*Gina Hagler is a is a master's degree candidate in the Science and Medical Writing through the Krieger School of Arts and Sciences, Advanced Academic Programs.

**Adam Book is a master's degree candidate in the Science and Medical Writing through the Krieger School of Arts and Sciences, Advanced Academic Programs.


####

About Johns Hopkins Institute for NanoBioTechnology
The Johns Hopkins Institute for NanoBioTechnology (INBT) at Johns Hopkins University brings together more than 175 researchers from the Bloomberg School of Public Health, Krieger School of Arts and Sciences, School of Medicine, Applied Physics Laboratory, and Whiting School of Engineering to create new knowledge and new technologies at the interface of nanoscience and medicine.

For more information, please click here

Contacts:
Johns Hopkins Institute for NanoBioTechnology
3400 North Charles Street
Baltimore, MD 21218


Phone: (410) 516-3423
Fax: (410) 516-2355

Copyright © Johns Hopkins Institute for NanoBioTechnology

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Possible Futures

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Announcements

A nano-roundabout for light December 10th, 2016

Keeping electric car design on the right road: A closer look at the life-cycle impacts of lithium-ion batteries and proton exchange membrane fuel cells December 9th, 2016

Further improvement of qubit lifetime for quantum computers: New technique removes quasiparticles from superconducting quantum circuits December 9th, 2016

Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016

Events/Classes

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

In IEDM 2016 Keynote, Leti CEO Says ‘Hyperconnectivity’, Human-focused Research and the IOT Promise Profound, Positive Changes December 7th, 2016

IEDM: Leti CEO Marie Semeria to Give Opening-day Keynote on Impact of ‘Hyperconnectivity’ and IoT: Speech to Portray Key Role Nonprofit Research and Technology Organizations Play in Making Technology More Efficient and Ensuring Safety and Security November 29th, 2016

Leti and Grenoble Partners Demonstrate World’s 1st Qubit Device Fabricated in CMOS Process: Paper by Leti, Inac and University of Grenoble Alpes Published in Nature Communications November 28th, 2016

Nanobiotechnology

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Deep insights from surface reactions: Researchers use Stampede supercomputer to study new chemical sensing methods, desalination and bacterial energy production December 2nd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project